Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to its treatment options for pain relief. The hospital, which opened in ...

Journavx’s pricing strategy, with a daily maintenance cost of $31, positions it at a premium compared to generic alternatives. This could lead to resistance from payers and potentially limit ...

The AHA today launched the new Care Delivery Transformation Framework that aims to support hospitals and health systems with tools and resources for the development and implementation of innovative ...

So going back to acute pain with JOURNAVX, you know that the distribution that we have discussed in terms of where pain prescriptions come from, let's call it, 50% in the fully retail segment ...

OpenAI is now fighting a court order to preserve all ChatGPT user logs—including deleted chats and sensitive chats logged through its API business offering—after news organizations suing over ...

Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pain relief with fewer side effects, positioning it as a potential new standard of care.